Eliem Therapeutics, Inc. (NASDAQ:ELYM – Get Free Report) crossed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $10.48 and traded as high as $11.54. Eliem Therapeutics shares last traded at $11.01, with a volume of 1,783,991 shares.
Eliem Therapeutics Stock Up 4.3%
The company has a market cap of $364.46 million, a price-to-earnings ratio of -23.11 and a beta of -0.39. The company’s 50-day moving average is $11.78 and its 200 day moving average is $10.51.
Eliem Therapeutics Company Profile
Eliem Therapeutics was a clinical-stage biopharmaceutical company focused on developing treatments for neurological and psychiatric disorders. Its research centered on therapies that modulate neuronal activity, with the goal of addressing conditions with significant unmet medical needs. One of its investigational programs was ETX-155, an oral compound designed to act on GABA-A receptors. The company studied the treatment for major depressive disorder and epilepsy; it was investigational and had not been established as a treatment for either condition.
Further Reading
- Five stocks we like better than Eliem Therapeutics
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for Eliem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eliem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
